Axonex AI Group Limited (AXNX) Stock Price & Analysis
Axonex AI Group Limited (AXNX) — MoonshotScore 17/100 (Weak band), calculated Nov 22, 2026. Price $0.8301 (-8.28%), as of the Nov 20, 2026 trading session; market cap $5.04M.
Educational signal · not a buy or sell recommendation · How to read this
Axonex AI Group Limited · AXNX · NASDAQ
Axonics, Inc. focuses on developing and commercializing sacral neuromodulation (SNM) systems for treating bladder and bowel dysfunction. Their rechargeable SNM system and Bulkamid product offer solutions for overactive bladder, urinary incontinence, and fecal incontinence.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Axonex AI Group (AXNX)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a fragile balance sheet and stalling growth, and it’s expensive on top — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Fragile; Valuation: Rich; Growth Durability: Shrinking; Momentum: Falling.
- quarterly revenue $167,051 (Q4 FY2026, quarter ended Mar 31, 2026)
- Altman Z -2.31 · Piotroski F 2
Holding back: weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 17 | Weak | |
| 17 | Weak | |
| 17 | Weak | |
| 17 | Weak | |
| 17 | Weak | |
| 17 | Weak |
The score was 17 in the stored Nov 21, 2026 snapshot and remains 17 in the current publication computed Nov 22, 2026 (0); the largest pillar moves were Business Quality +1 and Momentum +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.8301 | |
| Change on the day | -8.28% | |
| 52-week range | $0.68 – $18.35 | |
| Market capitalisation | $5.04M | |
| Shares traded on the day | 26.9K |
Price & events
Other perspectives
Council score for Axonex AI Group (AXNX): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 22, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 22, 2026, except a card that shows its own read date.
What is Axonex AI Group (AXNX), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Axonex AI Group Limited (AXNX) is listed on NASDAQ. It employs 36 people and is led by Hoi Lung Chan. In Q4 FY2026 it reported revenue of $167,051 and net income of -$222,175. The market values it at $5.04M.
What do the latest results show for Axonex AI Group (AXNX)?
Short answer · as of
The most recent reported quarter, Q4 FY2026, carried revenue of $167,051.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2026 | $167,051 | -$222,175 | -$0.22 (diluted) |
| Q2 FY2026 | $126,511 | -$1M | -$1.10 (diluted) |
| Q4 FY2025 | $963,447 | -$796,514 | -$0.91 (diluted) |
| Q3 FY2025 | $963,447 | -$796,514 | -$0.91 (diluted) |
Data check: No usable statement is on file for the period between Q4 FY2025 and Q2 FY2026; that quarter is left out rather than estimated. No usable statement is on file for the period between Q2 FY2026 and Q4 FY2026; that quarter is left out rather than estimated. Nothing in this table has been filled in or adjusted.
What are the financial strengths and risks for Axonex AI Group (AXNX)?
Short answer · as of
What is holding it back is weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -2.31 · Piotroski F 2. Trailing ratios: ROA -98.3% · current ratio 1.89.
Data-derived red flags
- Listing risk — at $0.8301 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -2.31 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How does Axonex AI Group compare with its peers?
Short answer
Axonex AI Group's score ranks 11th of 12 in the bounded comparison shown, against 11 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $25.73 Nov 20, 2026 | $119M | 36 5-pillar Nov 22, 2026 | |
| $0.35 Nov 20, 2026 | $13.5M | 35 5-pillar Nov 22, 2026 | |
| $2.73 Nov 20, 2026 | $39.6M | 33 5-pillar Nov 22, 2026 | |
| $9.25 Nov 20, 2026 | $283M | 29 5-pillar Nov 22, 2026 | |
| $1.02 Nov 20, 2026 | $5.10M | 28 5-pillar Nov 22, 2026 | |
| $1.13 Nov 20, 2026 | $17.1M | 25 5-pillar Nov 22, 2026 | |
| $1.29 Nov 20, 2026 | — | 25 5-pillar Nov 22, 2026 | |
| $32.22 Nov 20, 2026 | $333M | 20 5-pillar Nov 22, 2026 | |
| $0.67 Nov 20, 2026 | $7.16M | 19 5-pillar Nov 22, 2026 | |
| $6.39 Nov 20, 2026 | $15.0M | 18 5-pillar Nov 22, 2026 | |
| Axonex AI Group (AXNX) — this page | $0.8301 | $5.04M | 17 |
| $7.36 Nov 20, 2026 | $289M | 9 5-pillar Nov 22, 2026 | |
| $79.97 Sep 22, 2026 | $4.68B | — Model unavailable |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 1
- Identified insiders
- 1
- Purchases
- 1
- Sales
- 0
- Other transactions
- 0
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held AXNX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported AXNX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Axonex AI Group (AXNX)?
What Investors Ask About Axonex AI Group (AXNX)
These answers are editorial: 1 of these 9 answers is drawn from the AXNX research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for AXNX?
AXNX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Axonics, Inc. focuses on developing and commercializing sacral neuromodulation (SNM) systems for treating bladder and bowel dysfunction.
Is AXNX a good stock to buy?
Stock Expert AI does not rate AXNX buy, sell or hold. Axonex AI Group Limited carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the AXNX stock price today?
The last price recorded for Axonex AI Group Limited (AXNX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for AXNX?
The main risks for Axonics, Inc. include competition from established medical device companies, regulatory hurdles and reimbursement challenges, and product liability claims.
What are the key factors to evaluate for AXNX?
Axonex AI Group Limited (AXNX) holds a MoonshotScore in the low range. These regions have a large population base and increasing healthcare spending. Not financial advice.
How frequently does AXNX data refresh on this page?
AXNX's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven AXNX's recent stock price performance?
Axonex AI Group Limited (AXNX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative rechargeable SNM system. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AXNX overvalued or undervalued right now?
Axonex AI Group Limited (AXNX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of AXNX?
Fractional-share availability for Axonex AI Group Limited (AXNX) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 16 figures on this page — 10 from Financial Modeling Prep (FMP), 4 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com